FDA approves Evenity for osteoporosis

FDA approved Evenity romosozumab-aqqg from Amgen and UCB to treat osteoporosis in postmenopausal women at high risk of fracture.

Read the full 195 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE